Octave Bioscience to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Audio By Carbonatix

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug 28, 2025--

Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that its management team will be attending the Morgan Stanley 23 rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel in New York, NY.

About Octave Bioscience, Inc.

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes. For more information, visit www.octavebio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250828408782/en/

CONTACT: Caroline Corner

ICR Healthcare

caroline.corner@icrhealthcare.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: MENTAL HEALTH RESEARCH FINANCE NEUROLOGY BANKING PROFESSIONAL SERVICES HEALTH GENERAL HEALTH SCIENCE

SOURCE: Octave Bioscience, Inc.

Copyright Business Wire 2025.

PUB: 08/28/2025 04:59 PM/DISC: 08/28/2025 04:59 PM

http://www.businesswire.com/news/home/20250828408782/en